Conformetrix to Present at ELRIG Drug Discovery 2012 Company to Discuss Conformational Insights

Published: Sep 04, 2012

Manchester, UK, September 3 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will be presenting at ELRIG Drug Discovery 20121 on September 6 2012. The presentation, 'The application of ligand conformational preferences in drug discovery', will discuss how the tuning of conformational preferences can be used to optimise the potency of drug candidates. As well as insights from Conformetrix's proprietary preclinical drug discovery programmes, Senior Medicinal Chemist Barrie Martin will discuss projects in which the dynamic 3D-structures of two drug molecules were solved.

Conformetrix’s NMR technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development- stage compounds are likely to interact with their targets. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programmes.

1 ELRIG/SLAS Drug Discovery 2012, September 5-6 2012, Manchester, UK,

For further information please contact:

Conformetrix Ltd

Sam Williams, CEO +44 (0)7881 588947

Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185

About Conformetrix Ltd

Conformetrix is a Manchester, UK-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since Conformetrix's NMR technology shows what shapes molecules adopt when they are active, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more cheaply than by standard techniques such as X-ray crystallography. Conformetrix has solved structures for several large pharmaceutical companies, as well as developing proprietary drug programmes, and recently signed a collaboration with AstraZeneca. It has been funded since inception by specialist life science investor Aquarius Equity Partners. For more information, please go to

Back to news